Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer

被引：8

作者：

McCrea, Charles ^{[1
]}

Hettle, Robert ^{[1
]}

Gulati, Poonam ^{[1
]}

Taneja, Ankush ^{[2
]}

Rajora, Preety ^{[2
]}

机构：

[1] AstraZeneca, 136 Hills Rd,Acad House, Cambridge CB2 8PA, England

[2] BresMed, 906-912,JMD Megapolis,Sohna Rd, Gurugram 122018, Haryana, India

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 10卷 / 13期

关键词：

BRCA; breast cancer; breast cancer gene; HER2-negative; HER2; metastatic breast cancer; Olaparib; OPEN-LABEL; CHEMOTHERAPY; MULTICENTER; VELIPARIB; OVARIAN;

D O I：

10.2217/cer-2021-0097

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: Two poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and talazoparib are approved for patients with germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer. Methods: A Bayesian fixed-effects indirect treatment comparison (ITC) analysis was performed to simulate the comparative efficacy (primary outcome of progression-free survival [PFS]) and safety of PARP inhibitor monotherapy. Results: ITC of data from the OlympiAD (olaparib) and EMBRACA (talazoparib) studies suggested no significant difference in efficacy (PFS) between olaparib and talazoparib. However, there were differences in specific adverse events; patients receiving olaparib had a higher rate of nausea and vomiting, while those receiving talazoparib had a higher rate of alopecia and anemia. Discussion: These data support the benefit of the PARP inhibitor class in gBRCAm HER2-negative metastatic breast cancer.

引用

页码：1021 / 1030

页数：10

共 27 条

[1]

[Anonymous], 2018, Breast Cancer Facts and Figures

[2]

Deeks J.J., 2023, Cochrane handbook for systematic reviews of interventions

[3] Parp-2 is required to maintain hematopoiesis following sublethal γ-irradiation in mice [J].

Farres, Jordi ;

Martin-Caballero, Juan ;

Martinez, Carlos ;

Lozano, Juan J. ;

Llacuna, Laura ;

Ampurdanes, Coral ;

Ruiz-Herguido, Cristina ;

Dantzer, Francoise ;

Schreiber, Valerie ;

Villunger, Andreas ;

Bigas, Anna ;

Yelamos, Jose .

BLOOD, 2013, 122 (01) :44-54

[4]

FDA, 2018, TALZEENA TAL PRESCR

[5]

FDA, 2014, LYNPARZA OLAP PRESCR

[6] Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J].

Gelmon, Karen A. ;

Tischkowitz, Marc ;

Mackay, Helen ;

Swenerton, Kenneth ;

Robidoux, Andre ;

Tonkin, Katia ;

Hirte, Hal ;

Huntsman, David ;

Clemons, Mark ;

Gilks, Blake ;

Yerushalmi, Rinat ;

Macpherson, Euan ;

Carmichael, James ;

Oza, Amit .

LANCET ONCOLOGY, 2011, 12 (09) :852-861

[7] Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study [J].

Han, H. S. ;

Dieras, V. ;

Robson, M. ;

Palacova, M. ;

Marcom, P. K. ;

Jager, A. ;

Bondarenko, I. ;

Citrin, D. ;

Campone, M. ;

Telli, M. L. ;

Domchek, S. M. ;

Friedlander, M. ;

Kaufman, B. ;

Garber, J. E. ;

Shparyk, Y. ;

Chmielowska, E. ;

Jakobsen, E. H. ;

Kaklamani, V. ;

Gradishar, W. ;

Ratajczak, C. K. ;

Nickner, C. ;

Qin, Q. ;

Qian, J. ;

Shepherd, S. P. ;

Isakoff, S. J. ;

Puhalla, S. .

ANNALS OF ONCOLOGY, 2018, 29 (01) :154-161

[8]

Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0111-2, 10.1038/s41572-019-0122-z]

[9] Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial [J].

Hu, Xi-Chun ;

Zhang, Jian ;

Xu, Bing-He ;

Cai, Li ;

Ragaz, Joseph ;

Wang, Zhong-Hua ;

Wang, Bi-Yun ;

Teng, Yue-E ;

Tong, Zhong-Sheng ;

Pan, Yue-Yin ;

Yin, Yong-Mei ;

Wu, Chang-Ping ;

Jiang, Ze-Fei ;

Wang, Xiao-Jia ;

Lou, Gu-Yin ;

Liu, Dong-Geng ;

Feng, Ji-Feng ;

Luo, Jian-Feng ;

Sun, Kang ;

Gu, Ya-Jia ;

Wu, Jiong ;

Shao, Zhi-Min .

LANCET ONCOLOGY, 2015, 16 (04) :436-446

[10] Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial [J].

Hurvitz, Sara A. ;

Gocalves, Anthony ;

Rugo, Hope S. ;

Lee, Yung-Hun ;

Fehrenbacher, Louis ;

Mina, Lida A. ;

Diab, Sami ;

Blum, Joanne L. ;

Chakrabarti, Jayeta ;

Elmeliegy, Mohamed ;

DeAnnuntis, Liza ;

Gauthier, Eric ;

Czibere, Akos ;

Tudor, Iulia Cristina ;

Quek, Ruben G. W. ;

Litton, Jennifer K. ;

Ettl, Johannes .

ONCOLOGIST, 2020, 25 (03) :E439-E450

← 1 2 3 →